A randomized, blinded, placebo and positive-controlled 4-way crossover study to study the effect of multiple doses of apixaban on the QTc interval in healthy subjects.

Trial Profile

A randomized, blinded, placebo and positive-controlled 4-way crossover study to study the effect of multiple doses of apixaban on the QTc interval in healthy subjects.

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Nov 2015

At a glance

  • Drugs Apixaban (Primary) ; Moxifloxacin
  • Indications Thromboembolism
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top